Appendix 4C - Quarterly report
31 January 2017 Enclosed is the quarterly report for the period ending...
Read MoreCLINUVEL Newsletter - December 2016
20 December 2016 At the end of a calendar year we look...
Read MoreResults of Meeting
28 November 2016 In accordance with Listing Rule 3.13.2 and section 251AA...
Read MoreChair's Address to the Annual General Meeting
27 November 2017 I would like to commence my address by saying...
Read MoreManaging Director's AGM Presentation
27 November 2016 Good morning and welcome to CLINUVEL’s Annual General Meeting....
Read MoreCLINUVEL agrees with FDA on New Drug Application timelines
8 November 2016 CLINUVEL today announced that it met on 7 November with...
Read MoreResponse to Price Query
31 October 2016 Enclosed is CLINUVEL PHARMACEUTICALS LTD’s response to a price...
Read MoreNotice of Annual General Meeting/Proxy Form
26 October 2016 This Explanatory Memorandum has been prepared for the Shareholders...
Read MoreAppendix 4G
26 October 2016 Enclosed is the Corporate Governance Council Principles and Recommendations...
Read MoreCLINUVEL relocates Melbourne office
24 October 2016 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL...
Read MoreFDA erythropoietic protoporphyria (EPP) scientific workshop
24 October 2016 The US Food and Drug Administration (FDA) will today...
Read MoreSCENESSE® NICE ENGLAND UPDATE
18 October 2016 CLINUVEL [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today...
Read More